PARKINSON'S DISEASE · White paper
Parkinson's Disease Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About parkinson's disease — and why its trials are hard
Parkinson's Disease (PD) is a progressive neurodegenerative disorder driven by loss of dopaminergic neurons in the substantia nigra and the accumulation of alpha-synuclein Lewy bodies. First described by James Parkinson in 1817, it manifests through cardinal motor features (bradykinesia, resting tremor, rigidity, postural instability) alongside non-motor symptoms such as cognitive decline, mood disorders, autonomic dysfunction and sleep disturbance. Roughly 1 million Americans and nearly 10 million people worldwide live with PD, with prevalence rising sharply after age 60 as populations age. Pharmacotherapy remains symptomatic: levodopa/carbidopa is the cornerstone, supplemented by dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine and adenosine A2A antagonists, plus deep brain stimulation for advanced disease. Critically, despite decades of research no disease-modifying therapy has been approved, and multiple neuroprotective candidates have failed in late-phase trials. Clinical development is complicated by symptom heterogeneity, strong placebo responses, motor fluctuations and reliance on subjective rating scales, making robust endpoint selection and enrichment strategies essential for success.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Levodopa/Carbidopa (Sinemet) | 1975 | All stages; motor symptom control | Historical registration and PK studies | UPDRS Part III (motor) | Gold-standard motor benefit; remains most efficacious symptomatic therapy (magnitude varies by formulation) |
| Pramipexole (Mirapex) | 1997 | Early and advanced PD (dopamine agonist) | Early PD monotherapy trial (N=335) | UPDRS Parts II and III | UPDRS III improved +5.0 with pramipexole vs -0.8 placebo; UPDRS II +1.9 vs -0.4 |
| Ropinirole (Requip) | 1997 | Early and advanced PD (dopamine agonist) | Early PD 6-month trial (N=241) | % change UPDRS motor score | -22% ropinirole vs +4% placebo (26% placebo-corrected difference) |
| Rasagiline (Azilect) | 2006 | Monotherapy (early) and adjunct (advanced) MAO-B inhibitor | Adjunct OFF-time studies (N=472) | Daily OFF time (patient diaries) | OFF time reduced -1.9 h (1 mg) vs -0.9 h placebo (p<0.0001) |
| Safinamide (Xadago) | 2017 | Adjunct to levodopa for OFF episodes (MAO-B + glutamate modulation) | Study 2 (N=543) | Total daily ON time without troublesome dyskinesia; OFF time | ON time +0.99 h vs placebo (p<0.001); OFF time -1.06 h (p<0.001) |
| Istradefylline (Nourianz) | 2019 | Adjunct to levodopa/carbidopa for OFF episodes (adenosine A2A antagonist) | Pooled registration trials | Reduction in daily OFF time | Placebo-corrected OFF-time reduction ~0.7-0.75 h/day (unverified exact value) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in parkinson's disease development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Rasagiline (2 mg, disease modification) — ADAGIO (NCT00256204) | 2 mg/day delayed-start arm failed to show slowing of progression; only 1 mg met the primary endpoint | Inconsistent dose-response undermined a disease-modifying claim; delayed-start design ambiguity |
| Cinpanemab (anti-alpha-synuclein antibody) — SPARK (Biogen) | No effect on MDS-UPDRS or imaging vs placebo; program discontinued | Target engagement/timing questions; possible mismatch between peripheral antibody and intraneuronal aggregates |
| Isradipine (calcium channel blocker) — STEADY-PD III | Failed to slow clinical progression measured by UPDRS | Dihydropyridine dosing tolerability; effect too small to detect in early PD population |
Choosing the right endpoint
Primary endpoints that matter in parkinson's disease trials
- MDS-UPDRS Part III (motor examination) — Core efficacy measure of motor severity; subject to inter-rater variability, mitigated by rater training and video standardization
- Daily OFF time — Captured via patient home diaries; key adjunct-therapy endpoint but reliant on accurate self-report, improved with e-diaries and wearables
- ON time without troublesome dyskinesia — Balances symptom control against dyskinesia burden; central to advanced-PD adjunct trials
- PDQ-39 quality of life — Patient-reported disease-specific QoL; subjective, best paired with objective motor measures
- Non-Motor Symptoms Scale (NMSS) / MoCA — Assess autonomic, sleep, mood and cognitive domains; variable and fluctuating, requiring repeated longitudinal assessment
How iNGENū runs parkinson's disease trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Parkinson's Disease clinical trials — FAQs
Is there a cure or disease-modifying drug for Parkinson's Disease?
Why is levodopa still the standard of care after 50 years?
What makes Parkinson's trials difficult to run?
Ready to discuss your parkinson's disease trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal